Targeted Talks
Claim This Podcastby Targeted Oncology
Podcast Authority
Beta
Podcast Overview
<div>Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.</div>
Language
🇺🇲
Publishing Since
6/15/2020
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
Podcast Authority
BetaRecommendations available
Unlock the full report to see detailed tips
Recommendations available
Unlock the full report to see detailed tips
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
See how your show performs across every key metric
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
3 verified contact emails on file for Targeted Talks
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 1, 2026
S7 Ep18: Drowning in Data: How Oncologists Are Coping with Information Overload in the AI Era
<div> <p>In this episode of Treating Together, host Dr Pallav Mehta sits down with Dr Kurt Demel and Dr Yan Ji, 2 community-based medical oncologists practicing in the Twin Cities, to tackle a problem every oncologist feels but few have named clearly: information overload.</p><p>The conversation opens with a deceptively simple question: When does learning become overload? The group traces the line from the genuine joy of working in a constantly evolving field to the point where the sheer volume of trial data, survival end points, and subgroup analyses makes it hard to land on a clear recommendation for the patient in the room. Dr Ji offers a memorable framing for this: the "memory battery" that drains over the course of a clinic day, leaving even thorough research feeling unresolved when conflicting trials point in different directions.</p><p>From there, the discussion moves into how oncologists actually cope by leaning on colleagues through email threads and group chats, the growing divide between generalist and subspecialist practice, and how increasingly informed patients (armed with their own ChatGPT printouts) are reshaping the visit itself. The back half of the episode digs into AI's expanding role in oncology: ambient note-taking, evidence-summarization tools like OpenEvidence, and AI-assisted clinical trial matching, alongside real concerns about hallucinated summaries, erosion of foundational clinical reasoning in trainees, and the risk of applying trial data to patients who don't resemble the trial population. The episode closes on a note of cautious optimism—AI as a tool to clear away noise, not a replacement for the clinical judgment and human connection that the panel agrees remains the real value an oncologist brings to a patient.</p></div>
June 17, 2026
S7 Ep17: Navigating the 505(b)(2) Pathway: Operational, Clinical, and Economic Strategies for Oncology Practices
<div> <p>In this episode, managing editor Sabrina Serani sits down with 3 experts at the intersection of oncology pharmacy, health informatics, and drug distribution to unpack the 505(b)(2) regulatory pathway and what it means for cancer centers navigating today's complex drug landscape.</p><p><strong>Guests:<br></strong><br></p></div><ul> <li> <strong>Jessica White, PharmD, </strong>Vice President, Specialty Programs & Portfolio Management at McKesson</li> <li> <strong>Derek Burns, PharmD, </strong>Senior Director, MID Solutions at McKesson</li> <li> <strong>Nick Brady, </strong>Director, Health Informatics at Central Arkansas Radiation Therapy Institute (CARTI)</li> </ul><div> <p><strong>What We Cover:<br></strong><br>The 505(b)(2) Pathway Explained — Jessica breaks down how the 505(b)(2) new drug application differs from a traditional NDA, allowing drug developers to build on existing FDA-recognized data through bridging studies. The result: faster approvals, lower development costs, and drugs that improve on — rather than simply duplicate — what's already on the market.</p><p>Why Oncology, Why Now — Nick explains how 505(b)(2) drugs address a critical pain point in oncology practice: supply disruption. When reference products go on allocation or become unavailable, these drugs provide a meaningful alternative — and in some cases, meaningful clinical improvements like reduced toxicity, modified dosage forms, or improved adherence.</p><p>The Real Friction Points — Derek identifies where practices actually get stuck: not at the clinical level, but in operations. Launching without a brand name, missing J-codes, absent ASP data, and gaps in the CMS NDC crosswalk all create hesitation in revenue cycle teams. The underlying problem, he argues, is almost never resistance to innovation — it's undefined coverage, coding, and workflow clarity at launch.</p><p>Who Needs to Be at the Table — Nick walks through Carti's internal adoption process, emphasizing that economic evaluation must run in parallel with patient impact assessment. A cross-functional team — pre-certification, pharmacy (both infusion and dispensing), billing and coding, and claims monitoring — needs to move together, with a single source of truth so that no one on the front lines is working from conflicting information.</p><p>Practical Strategies for Adoption — The group converges on two key approaches: front-load organizational alignment before the first dose is given, and start narrow with a defined pilot population before any broad rollout. Derek and Jessica also stress the value of a designated practice champion who can coordinate across departments and pressure-test coverage and economics in advance.</p><p>The Patient at the Center — When everything is working, patients experience seamless transitions between products, fewer delays, and — in some cases — therapies that are easier to tolerate and stay on. The panel emphasizes that a well-integrated 505(b)(2) strategy should be invisible to the patient while delivering real downstream clinical and economic benefit.</p><p>Safety Considerations — Derek underscores that practices managing multiple agents within the same drug category face real risks around dispensing, billing, and administration if labeling and workflows aren't airtight. Jessica notes that the industry is correcting course, with more manufacturers now launching 505(b)(2) products with distinct brand names — reducing the risk of misidentification.</p><p>Where the Pipeline Is Headed — Jessica closes with a look at the road ahead: more branded manufacturers entering the 505(b)(2) space, a growing pipeline from traditional generic manufacturers focused on oncology, and a strategic emphasis on supply redundancy and clinical improvements for older, well-established agents that have experienced drug shortages.</p><p><strong>Key Takeaways:<br></strong><br></p></div><ul> <li>Treat 505(b)(2) drugs as an operational, clinical, and financial tool, not just an economic play.</li> <li>Every oncology practice will likely carry multiple agents in the same category; managing that inventory safely is non-negotiable.</li> <li>If you've seen one 505(b)(2), you've seen one. Ask what's actually different, what the evidence supports, and how it fits your patients.</li> <li>"Not yet" is more accurate than "never": even practices not ready to adopt should be educating staff now.</li> </ul>
May 20, 2026
S7 Ep16: ASCO 2026 Preview: Late-Breaking Abstracts Poised to Reshape the Treatment Landscape
Ahead of the 2026 ASCO Annual Meeting, Sabrina Serani, managing editor of Targeted Oncology, previews the late-breaking abstracts most likely to influence clinical practice across breast, colorectal, prostate, and lung cancer, as well as in metastatic uveal melanoma, a disease that has gone without an effective systemic therapy for decades. From VIKTORIA-1 in PIK3CA-mutant metastatic breast cancer to BREAKWATER's first look at overall survival in BRAF V600E-mutant colorectal cancer, this episode breaks down the science, the clinical context, and the questions that full data will need to answer.
88 total episodes available
Recent guests on Targeted Talks
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Alfred L Garfall MD
Guest
David A Russler-Germain
Guest
Aditya Bardia
Guest
Douglas Flora MD LSSBB FACCC
Guest
Similar Podcasts
Discover related shows you might enjoy
Deep-dive analytics for Targeted Talks
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Targeted Talks?
<div>Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.</div> - How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 9 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.